Literature DB >> 11566277

Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate.

Q Peng1, A M Soler, T Warloe, J M Nesland, K E Giercksky.   

Abstract

Topical photodynamic therapy (PDT) of superficial basal cell carcinoma (BCC) with 5-aminolevulinic acid (ALA) has achieved promising clinical results. However, the efficacy of this therapy for thick BCC is dramatically decreased by a limited diffusion of hydrophilic ALA into the tumor. Lipophilic esters of ALA may enhance their penetration into the lesion. In this randomized, open clinical study, microscopic fluorescence photometry incorporating a light-sensitive thermo-electrically cooled charge-coupled device (CCD) camera was employed to investigate the penetration of methyl 5-aminolevulinate-induced porphyrin fluorescence in thick BCC lesions. Both the distribution pattern and the amount of porphyrins in 32 lesions of 16 patients were studied after topical application of 16, 80 or 160 mg/g of methyl 5-aminolevulinate for 3 or 18 h. A highly selective and homogeneous distribution of methyl 5-aminolevulinate-induced porphyrin fluorescence was seen in all lesions studied, with much less fluorescence in the adjacent normal skin tissues. In lesions of up to 2 mm thickness the application of 160 mg/g methyl 5-aminolevulinate for 3 h showed the highest ratio of porphyrin fluorescence depth to tumor depth (0.98+/-0.04), thus providing a biologic rationale for a clinical PDT trial with this regimen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566277     DOI: 10.1016/s1011-1344(01)00173-7

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  22 in total

1.  Evidence of 5-aminolevulinic acid (ALA) penetration increase due to microdrilling in soft tissue using femtosecond laser ablation.

Authors:  Gustavo Nicolodelli; Cristina Kurachi; Raquel Ferreira Rego; Tarek Omairi; Vanderlei Salvador Bagnato
Journal:  Lasers Med Sci       Date:  2012-01-22       Impact factor: 3.161

2.  Imaging a photodynamic therapy photosensitizer in vivo with a time-gated fluorescence tomography system.

Authors:  Weirong Mo; Daniel Rohrbach; Ulas Sunar
Journal:  J Biomed Opt       Date:  2012-07       Impact factor: 3.170

3.  Oleic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy.

Authors:  Maria Bernadete Riemma Pierre; Eduardo Ricci; Antonio Cláudio Tedesco; Maria Vitória Lopes Badra Bentley
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

Review 4.  Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.

Authors:  Baozhong Zhao; Yu-Ying He
Journal:  Expert Rev Anticancer Ther       Date:  2010-11       Impact factor: 4.512

5.  White light-informed optical properties improve ultrasound-guided fluorescence tomography of photoactive protoporphyrin IX.

Authors:  Brendan P Flynn; Alisha V DSouza; Stephen C Kanick; Scott C Davis; Brian W Pogue
Journal:  J Biomed Opt       Date:  2013-04       Impact factor: 3.170

6.  Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.

Authors:  Sanjay Anand; Golara Honari; Tayyaba Hasan; Paul Elson; Edward V Maytin
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

7.  Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.

Authors:  Stephen Chad Kanick; Scott C Davis; Yan Zhao; Tayyaba Hasan; Edward V Maytin; Brian W Pogue; M Shane Chapman
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

8.  5-aminolevulinic acid ester-induced protoporphyrin IX in a murine melanoma cell line.

Authors:  Flavia C B Vena; Rozane F Turchiello; Isabelle Laville; Sophie Pigaglio; Jocelyne Blais; Antonio C Tedesco
Journal:  Lasers Med Sci       Date:  2004       Impact factor: 3.161

9.  Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.

Authors:  E Blake; J Allen; C Thorn; A Shore; A Curnow
Journal:  Lasers Med Sci       Date:  2012-08-28       Impact factor: 3.161

10.  Bowen's disease - a review of newer treatment options.

Authors:  Thorsten Neubert; Percy Lehmann
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.